Key result
In patients with chronic obstructive pulmonary disease, inhaled anticholinergics increased the risk of major cardiovascular events by 58% compared to placebo or active controls.
Why the study?
In patients with chronic obstructive pulmonary disease (COPD), do inhaled anticholinergics increase risk of major cardiovascular events?
Meta-Analysis (n=14,783)
In patients with chronic obstructive pulmonary disease (COPD), do inhaled anticholinergics increase risk of major cardiovascular events?
While a meta-analysis suggested inhaled anticholinergics increase cardiovascular risk in COPD, the large, long-term UPLIFT trial provides reassurance that tiotropium added to usual therapy does not increase cardiovascular events or mortality.
Answers are grounded in this paper and cite their sources.
May raise CV event risk in COPD; leaves open net safety pending large RCT confirmation like UPLIFT.
Review: inhaled anticholinergics increase risk of major cardiovascular events in COPD QUESTION In patients with chronic obstructive pulmonary disease (COPD), do inhaled anticholinergics increase risk of major cardiovascular events?
No takes yet. Share an insight, caveat, or question.
Matthew B. Stanbrook (2009) conducted a meta-analysis in Chronic obstructive pulmonary disease (COPD) (n=14,783). Inhaled anticholinergics vs. Placebo or active drugs was evaluated on Major cardiovascular event (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death) (RRI 58%, 95% CI 21 to 106). In patients with chronic obstructive pulmonary disease, inhaled anticholinergics increased the risk of major cardiovascular events by 58% compared to placebo or active controls.
Synapse has enriched 10 related papers. Consider them for comparative context: